53692-87-8

Upstream product

• 64-17-5 ethanol 
• 80-58-0 2-Bromobutyric acid 
• 74-96-4 ethyl bromide 
• 141-52-6 sodium ethanolate 
• 105-34-0 methyl 2-cyanoacetate 
• 124-41-4 sodium methylate 
• 75-03-6 ethyl iodide 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 24131-07-5 methyl 2-cyano-2-phenylbutanoate 
• 1609240-10-9 1-(4-chlorophenyl)-3-ethyl-7-fluoroquinoxalin-2(1H)-one 4-oxide 
• 1447934-40-8 3-ethyl-7-methoxy-1-(4-methylphenyl)quinoxalin-2(1H)-one 4-oxide 
• 1609240-09-6 1-(2,6-dimethylphenyl)-3-ethyl-7-phenylquinoxalin-2(1H)-one 4-oxide 
• 1609240-08-5 3-ethyl-7-fluoro-1-phenylquinoxalin-2(1H)-one 4-oxide 
• 1609240-02-9 7-chloro-1-(2,6-dimethylphenyl)-3-ethylquinoxalin-2(1H)-one 4-oxide 
• 1455088-12-6 2-{[(1-cyano-4-hydroxy-7-phenoxyisoquinoline-3-carbonyl)amino]methyl}-butyric acid 
• 1455092-92-8 2-{[(1-cyano-4-hydroxy-7-phenoxyisoquinoline-3-carbonyl)amino]methyl}-butyric acid methyl ester 
• 1447934-43-1 6-(benzyloxy)-2-ethyl-4-(4-methylphenyl)-3,4-dihydro-1λ⁵,4-quinoxaline-1,3-dione 
• 1447934-48-6 methyl 2-[7-(benzyloxy)-3-ethyl-1-(4-methylphenyl)-2-oxo-1,2-dihydroquinoxalin-6-yl]-2-cyanobutanoate 
• 1447934-45-3 methyl 2-cyano-2-[3-ethyl-7-methoxy-1-(4-methylphenyl)-2-oxo-1,2-dihydroquinoxalin-6-yl]butanoate 
• 1447934-54-4 6-butyl-4-(2,6-dimethylphenyl)-2,8-diethyl-3,7-oxo-3H,4H,6H,7H,8H-pyrrolo[2,3-g]quinoxaline-8-carbonitrile 
• 1447934-53-3 6-butyl-4-(4-ethoxyphenyl)-2,8-diethyl-3,7-dioxo-3H,4H,6H,7H,8H-pyrrolo[2,3-g]quinoxaline-8-carbonitrile 
• 1447934-52-2 6-butyl-4-(4-chlorophenyl)-2,8-diethyl-3,7-dioxo-3H,4H,6H,7H,8H-pyrrolo[2,3-g]quinoxaline-8-carbonitrile 

Relevant academic research and scientific papers

4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS

The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.

Cephalosporin compounds

The present invention relates to new cephalosporin compounds of the formula(I), pharmaceutically acceptable non-toxic salts thereof, and physiologically hydrolyzable esters and solvates thereof, which have potent and broad antibacterial activities STR1 wherein R1 is a C1?4 alkyl, C3?4 alkenyl, C3?4 alkynyl group, or --C(Ra)(Rb)CO2 H1 wherein Ra and Rb are the same or different, and each is a hydrogen atom or a C1?4 alkyl group, or Ra and Rb form a C3?7 cycloalkyl group with the carbon atom to which they are linked; R2 is a C1?4 alkyl, C3?4 alkenyl or C3?4 cycloalkyl group, a substituted or unsubstituted amino group, or a substituted or unsubstituted phenyl group; R3 is hydrogen or a C1?4 alkyl group; and Q is N or CH. The invention further relates to a process for preparing said compounds, and to pharamaceutical compositions containing said compounds.